Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batch Consistency Study of 13-valent Pneumococcal Conjugate Vaccine in 2-month-old Infants
CTR20254448Phase 3Active
- Sponsor
- Antejin
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Antejin. Started Nov 2025; status: active.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20254448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254448.